List of Excipients in Branded Drug OMNARIS

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Physicians Total Care Inc	OMNARIS	ciclesonide	54868-6020	CARBOXYMETHYLCELLULOSE SODIUM	2028-02-01
Physicians Total Care Inc	OMNARIS	ciclesonide	54868-6020	CELLULOSE, MICROCRYSTALLINE	2028-02-01
Physicians Total Care Inc	OMNARIS	ciclesonide	54868-6020	EDETATE SODIUM	2028-02-01
Physicians Total Care Inc	OMNARIS	ciclesonide	54868-6020	HYDROCHLORIC ACID	2028-02-01
Physicians Total Care Inc	OMNARIS	ciclesonide	54868-6020	HYPROMELLOSE	2028-02-01
Physicians Total Care Inc	OMNARIS	ciclesonide	54868-6020	POTASSIUM SORBATE	2028-02-01

Omnaris Excipient Strategy and Commercial Opportunities in Ciclesonide Nasal Spray

Last updated: August 1, 2026

Omnaris is a preservative-free, aqueous nasal suspension containing 50 mcg of ciclesonide per spray. Its commercial value is tied less to a novel excipient than to the coordinated use of cellulose-based suspension and mucoadhesive excipients, polysorbate 80, sodium chloride, citrate buffering, and a metered nasal-spray device. The main opportunities are generic or authorized-generic development, device and formulation optimization, regional lifecycle products, and contract-manufacturing capabilities for low-dose corticosteroid suspensions.

What is Omnaris and how is its formulation designed?

Omnaris is the U.S. brand name for ciclesonide nasal spray, indicated for the treatment of seasonal and perennial allergic rhinitis. Each actuation delivers 50 mcg of ciclesonide from an aqueous suspension. The product is preservative-free and supplied in a metered-dose nasal-spray container. [1]

Ciclesonide is a corticosteroid prodrug. After administration, local esterases convert it to desisobutyryl ciclesonide, the pharmacologically active metabolite. The formulation therefore must deliver a low dose uniformly to the nasal mucosa while limiting systemic exposure.

The labeled inactive ingredients are:

Excipient or component	Primary formulation function
Microcrystalline cellulose	Suspending agent and rheology modifier
Carboxymethylcellulose sodium	Suspending, thickening, and mucoadhesive agent
Polysorbate 80	Wetting and dispersion aid
Sodium chloride	Tonicity adjustment
Sodium citrate	Buffering and pH control
Hydrochloric acid	pH adjustment
Purified water	Aqueous vehicle
Metered nasal-spray device	Dose measurement and delivery

The formulation does not depend on a preservative. That design reduces exposure to preservative-related irritation and supports differentiation in patients who use nasal sprays chronically.

What excipients protect the commercial performance of Omnaris?

The cellulose system is the core excipient strategy. Microcrystalline cellulose and sodium carboxymethylcellulose create a structured aqueous suspension that keeps poorly water-soluble ciclesonide distributed between doses. The same system can increase residence time on the nasal mucosa.

Polysorbate 80 supports wetting of the hydrophobic drug particles. Without adequate wetting, ciclesonide could agglomerate, settle unevenly, or produce inconsistent delivered doses. The surfactant concentration must remain low enough to limit irritation and avoid excessive foam or unstable interfacial behavior.

Sodium chloride adjusts osmotic properties. Nasal products that are substantially hypotonic or hypertonic can cause burning, discomfort, and reflex clearance. Sodium citrate and hydrochloric acid establish the target pH range and help maintain chemical stability.

Why the preservative-free design matters

Preservative-free nasal products can be attractive for:

• Long-term allergic-rhinitis treatment
• Patients with nasal irritation or sensitivity
• Pediatric and chronic-use segments
• Specialist prescribing where tolerability is a commercial differentiator
• Premium branded or authorized-generic positioning

The tradeoff is a higher microbiological-control burden. A preservative-free multidose suspension requires validated manufacturing controls, container-closure protection, in-use microbiological testing, and a reliable actuator. The device and formulation must operate as a single product rather than as independent components.

How does Omnaris compare with other intranasal corticosteroids?

Omnaris competes with fluticasone propionate, fluticasone furoate, mometasone furoate, budesonide, triamcinolone acetonide, and beclomethasone dipropionate products. The commercial comparison is driven by dose, formulation, scent, preservative status, device performance, age labeling, price, and generic availability.

Product	Active ingredient	General dosage form	Preservative-free positioning	Competitive status
Omnaris	Ciclesonide	Aqueous suspension	Yes	Brand and generic-entry opportunity
Flonase and generics	Fluticasone propionate	Aqueous suspension	Product-dependent	Broad generic competition
Flonase Sensimist and generics	Fluticasone furoate	Aqueous suspension	Product-dependent	Strong OTC and branded presence
Nasonex and generics	Mometasone furoate	Aqueous suspension	Product-dependent	Mature generic market
Rhinocort and generics	Budesonide	Aqueous suspension	Product-dependent	Mature generic and OTC competition
Nasacort and generics	Triamcinolone acetonide	Aqueous suspension	Product-dependent	Mature OTC competition
Beconase AQ	Beclomethasone dipropionate	Aqueous suspension	Product-dependent	Older, less dominant platform

Omnaris may retain formulation-level differentiation through its preservative-free design and ciclesonide pharmacology. That differentiation is difficult to protect commercially once the active ingredient and core dosage form become available to generic manufacturers.

What commercial opportunities exist for Omnaris excipients?

Generic and authorized-generic development

The principal opportunity is an ANDA or equivalent regional generic based on the same qualitative excipient framework. A manufacturer can use microcrystalline cellulose, carboxymethylcellulose sodium, polysorbate 80, sodium chloride, citrate, hydrochloric acid, and water while optimizing quantitative composition and process parameters.

The critical development targets are:

• Delivered dose uniformity
• Spray content uniformity
• Particle-size distribution
• Redispersibility after storage
• Plume geometry
• Droplet-size distribution
• Priming and repriming behavior
• Adhesion to the nasal actuator
• Microbial quality
• Chemical and physical stability
• Device-shake instructions and patient usability

A generic product does not need to duplicate every formulation parameter. It must demonstrate pharmaceutical equivalence and bioequivalence through the applicable regulatory pathway. For nasal suspensions, device performance and local delivery can create a higher technical burden than for conventional oral solid dosage forms.

Excipient substitution and formulation modernization

A developer could investigate alternatives to the Omnaris excipient system, including:

• Alternative cellulose derivatives
• Poloxamers or other nonionic surfactants in place of polysorbate 80
• Novel mucoadhesive polymers
• Lower-viscosity suspension systems
• Nanocrystalline or micronized drug dispersions
• In situ gelling systems
• Unit-dose preservative-free packaging
• Spray pumps with improved dose recovery

Substitution creates regulatory and patent risk if the original product contains protected formulation features. It also increases the need for comparative performance data. A different suspending system can alter sedimentation, redispersion, spray pattern, mucosal deposition, and delivered dose.

Excipient supplier opportunities

The excipient supply chain can support Omnaris-type products through pharmaceutical-grade materials with tight control of:

• Viscosity
• Degree of substitution for sodium carboxymethylcellulose
• Particle-size distribution for microcrystalline cellulose
• Microbial limits
• Endotoxin profile
• Peroxide and aldehyde levels in polysorbate 80
• Lot-to-lot hydration behavior
• Compatibility with ciclesonide and the spray container

A supplier that can provide compendial material with controlled rheology and regulatory documentation may obtain a competitive advantage. For nasal suspensions, nominal compendial compliance is not sufficient. Functional performance can change materially with polymer grade, hydration time, mixing energy, and order of addition.

What formulation patents protect Omnaris-type products?

The relevant intellectual-property categories are broader than the brand name. A ciclesonide nasal-spray program can involve patents covering:

1. Ciclesonide or active-metabolite chemistry
2. Intranasal administration and allergic-rhinitis treatment
3. Particle-size distribution and micronization
4. Aqueous suspension composition
5. Cellulose-based suspending systems
6. Preservative-free multidose packaging
7. Metered-dose nasal-spray devices
8. Manufacturing and homogenization processes
9. Stability and dose-uniformity controls
10. Pediatric or patient-specific dosing regimens

The U.S. product was approved under NDA 21-343. The FDA prescribing information identifies ciclesonide nasal spray as a 50-mcg-per-spray product and describes the inactive ingredients and delivery system. [1] Patent status should be reviewed through the current FDA Orange Book, USPTO records, and relevant court dockets because listed patents, expiration dates, pediatric extensions, and litigation outcomes can change over time. [2,3]

A formulation developer should not assume that the absence of an active-ingredient patent leaves the product unprotected. Nasal-spray device claims, manufacturing claims, and formulation claims can remain commercially relevant after core compound protection expires.

When did Omnaris lose exclusivity and what generic-entry risks exist?

Omnaris received FDA approval in 2006. The original U.S. market-exclusivity period has expired, and the product is exposed to generic competition under the ANDA framework. [1,2]

The principal generic-entry risks are:

Risk area	Commercial effect
Active-ingredient availability	Lowers the barrier to ciclesonide supply
Mature nasal-corticosteroid market	Compresses price and formulary leverage
Device equivalence	Can delay approval or increase development cost
Local bioequivalence	Creates technical uncertainty for generic applicants
Preservative-free manufacturing	Requires stronger microbiological controls
Formulation patents	May delay or narrow launch timing
Low unit cost of established products	Limits premium pricing
OTC competition	Reduces branded prescription demand

Paragraph IV challenges may target any unexpired Orange Book-listed patent. A first applicant making a Paragraph IV certification may obtain 180-day generic exclusivity if it satisfies the statutory requirements and receives approval. The business value depends on the number of applicants, litigation outcomes, settlement terms, and whether the reference product has meaningful remaining prescription volume.

What is the FDA regulatory status of Omnaris?

Omnaris was approved by the FDA as a prescription nasal spray for seasonal and perennial allergic rhinitis. The product’s regulatory profile is built around an aqueous suspension, a metered-dose pump, and a preservative-free multidose presentation. [1]

For a generic applicant, the regulatory work is likely to focus on:

• Pharmaceutical equivalence
• Comparative device performance
• Spray content uniformity
• Droplet and particle-size distributions
• Priming and repriming
• In vitro release or performance testing
• Stability through labeled shelf life
• Microbiological quality
• Human factors and device instructions where applicable

A reformulated product using different excipients may require a more extensive regulatory package than a close qualitative and quantitative formulation. Changes to the cellulose system or surfactant can affect local deposition and may complicate bioequivalence arguments.

What manufacturing and IP barriers affect ciclesonide nasal sprays?

The main manufacturing barrier is not the aqueous vehicle. It is reproducible suspension processing at a very low drug concentration.

A commercial process must control:

• Ciclesonide micronization
• Wetting and deagglomeration
• Polymer hydration
• Mixing sequence
• Shear exposure
• Bulk holding time
• Fill-volume accuracy
• Container-closure compatibility
• Pump metering
• Suspension homogeneity during filling

The drug concentration is low relative to the total formulation mass. Small differences in particle settling or pump recovery can produce clinically relevant dose variation. A developer also must validate the number of labeled sprays, including performance near the end of container life.

Potential IP barriers include claims directed to particle size, excipient ratios, suspension rheology, device components, and manufacturing conditions. A design-around strategy can use a different polymer system or device, but the change must preserve dose uniformity and nasal tolerability.

Which companies are positioned to challenge or compete with Omnaris?

Competition comes from three groups:

1. Generic ciclesonide developers
2. Companies selling other intranasal corticosteroids
3. OTC and branded manufacturers with differentiated nasal devices

Large generic manufacturers have an advantage in regulatory infrastructure, respiratory-device experience, and procurement scale. Specialty pharmaceutical companies may compete through preservative-free packaging, improved spray comfort, or regional licensing.

The most credible commercial entrants are likely to use one of two strategies:

• A close generic using the established cellulose suspension platform
• A differentiated product using a new pump, unit-dose package, or improved mucoadhesive system

A close generic is more likely to achieve near-term approval. A differentiated formulation has greater development risk but may support a higher price or a targeted licensing transaction.

How strong is the Omnaris formulation estate?

The formulation estate is strategically moderate rather than broad. The product has a recognizable formulation architecture, but most listed excipients are established pharmaceutical materials with extensive prior art. Protection is more likely to depend on the combination of:

• Ciclesonide particle characteristics
• Quantitative excipient ranges
• Suspension behavior
• Preservative-free presentation
• Device and actuator configuration
• Manufacturing controls

The commercial defensibility of the product therefore depends on the interaction between formulation IP, regulatory complexity, physician familiarity, and remaining market demand. Excipient selection alone is unlikely to support durable exclusivity.

What licensing and lifecycle opportunities exist?

Potential licensing opportunities include:

Regional rights

Ciclesonide nasal spray rights can be licensed by territory where the product has regulatory approval, limited local competition, or established specialist distribution. The value depends on market access, reimbursement, and the availability of generic corticosteroids.

Device licensing

A device company could license a low-residual-volume, preservative-free nasal actuator compatible with ciclesonide suspension. The device must maintain dose accuracy despite settling and patient-to-patient differences in shaking and priming.

Excipient platform licensing

A controlled-rheology cellulose system could be licensed for multiple intranasal corticosteroids. The platform would have greater value if it demonstrates improved redispersion, lower variability, or reduced nasal irritation across more than one active ingredient.

Authorized generic arrangements

The brand owner or current rights holder may pursue an authorized-generic model to retain channel access after generic entry. The opportunity is strongest where the product still has prescription demand but lacks durable price protection.

What are the revenue and market-exposure considerations?

Omnaris is exposed to the economics of a mature allergy market. Revenue pressure comes from generic fluticasone, mometasone, budesonide, and triamcinolone products, as well as OTC switching.

A commercial model should quantify:

• Current prescription volume
• Net price after rebates
• Payer formulary position
• Generic substitution rate
• Seasonal demand concentration
• Pediatric share
• Preservative-free prescribing
• Distribution cost
• Device manufacturing cost
• Minimum efficient batch size
• Remaining brand or regional rights

The excipient cost is unlikely to determine product economics. The major cost drivers are ciclesonide API, micronization, suspension processing, pump components, filling, quality testing, and regulatory compliance. A low-cost excipient substitution has limited value if it reduces spray uniformity or increases batch rejection.

How should a company prioritize an Omnaris-type development program?

A practical sequence is:

1. Confirm current regulatory and Orange Book status.
2. Map active and expired patents by jurisdiction.
3. Reconstruct the reference formulation and device performance.
4. Screen cellulose grades for viscosity and redispersion.
5. Establish ciclesonide particle-size controls.
6. Compare polysorbate 80 with alternative wetting agents.
7. Test preservative-free microbiological protection through container and process controls.
8. Generate comparative spray-performance data.
9. Conduct a freedom-to-operate review covering formulation, device, and process claims.
10. Select a generic, authorized-generic, or differentiated lifecycle strategy.

Key Takeaways

• Omnaris uses a preservative-free aqueous suspension of ciclesonide.
• Microcrystalline cellulose and sodium carboxymethylcellulose are the central suspension and mucoadhesive excipients.
• Polysorbate 80 supports wetting and dispersion of the poorly water-soluble corticosteroid.
• Sodium chloride, sodium citrate, hydrochloric acid, and purified water control tonicity, pH, and the aqueous vehicle.
• The main commercial opportunity is generic or authorized-generic ciclesonide nasal spray.
• Device performance, suspension homogeneity, and preservative-free microbiological control are the main technical barriers.
• Excipient substitution is possible but can alter nasal deposition, dose uniformity, and regulatory requirements.
• Formulation IP is most likely to matter through excipient combinations, particle characteristics, device claims, and manufacturing processes.
• The product competes in a mature intranasal corticosteroid market with substantial generic and OTC pressure.
• A differentiated device or controlled-rheology platform may create more value than a simple excipient-cost reduction.

FAQs

Is Omnaris a solution or a suspension?

Omnaris is an aqueous suspension. Ciclesonide is dispersed in the vehicle rather than fully dissolved.

Is Omnaris preservative-free?

Yes. The labeled formulation does not use a conventional antimicrobial preservative. The multidose presentation therefore depends on manufacturing controls, container-closure performance, and validated in-use microbiological protection.

Which excipient makes Omnaris mucoadhesive?

Sodium carboxymethylcellulose contributes to viscosity, suspension stability, and mucoadhesion. Microcrystalline cellulose also supports the structured suspension system.

Can polysorbate 80 be replaced in a ciclesonide nasal spray?

It can be investigated as part of a reformulation program, but replacement may change wetting, particle agglomeration, spray performance, chemical stability, and nasal tolerability.

What is the main development risk for a generic Omnaris product?

The main risk is reproducing consistent local nasal delivery from a low-dose suspension. Dose uniformity, redispersion, particle-size distribution, pump performance, and device equivalence require coordinated formulation and process control.

References

1. U.S. Food and Drug Administration. (2006). Omnaris (ciclesonide) nasal spray prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations.
3. U.S. Patent and Trademark Office. (n.d.). Patent Center and patent search resources.
4. U.S. Food and Drug Administration. (1999). Guidance for industry: Nasal spray and inhalation solution, suspension, and spray drug products: Chemistry, manufacturing, and controls documentation.
5. U.S. Food and Drug Administration. (2003). Guidance for industry: Bioavailability and bioequivalence studies for nasal aerosols and nasal sprays.